New hope for kids with rare cancer: sirolimus combo shows promise
NCT ID NCT06341998
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tested a new combination of drugs (sirolimus plus chemotherapy) in 32 children with recurrent or refractory yolk sac tumors, a rare type of germ cell tumor. The goal was to see if the combination could shrink tumors and improve survival. The treatment was given in cycles over several weeks, with regular monitoring of tumor markers and imaging.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
sirolimus combined with nab-paclitaxel, ifosfamide, and carboplatin
What this could lead to
If successful, this combination could offer a new treatment option for children with yolk sac tumors that have not responded to standard chemotherapy.
What could go wrong
This is a small, early-phase study with only 32 participants. The results may not apply to all patients, and the combination may cause significant side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GERM CELL TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Shandong Cancer Hospital and Institute
Jinan, Shandong, 250117, China